Nls pharmaceutics secures exclusive global license for next-generation non-sulfonamide dual orexin agonist platform

The exclusive license agreement grants nls pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies. medications activating dual ox1r/ox2r target a broader range of mechanisms involved in neurologic disorders including narcolepsy and other hypersomnolence disorders additional targets covered by the exclusive license agreement include cathepsins, sigma receptors and catecholaminergic inhibition, addressing neuroprotection, neuroinflammation and neurotransmission.
NLSP Ratings Summary
NLSP Quant Ranking